McGowan Institute for Regenerative Medicine faculty member Robert Kormos, MD, the director of the Artificial Heart Program, co-director of Heart Transplantation at University of Pittsburgh Medical Center, and the medical director of Vital Engineering, has been named by Allezoe Medical Holdings as a member of its wholly-owned subsidiary Organ Transport Systems' Medical Advisory Board (MAB). Organ Transport Systems (OTS) revealed that it is in preparations for clinical trials of its LifeCradle®, beginning with applications of its technology to donor heart preservation. OTS has selected the heart as the first focus of its clinical trials due to the pressing need for heart sharing in light of the prevalence of heart disease.
OTS, through its LifeCradle®, aims to directly address the discrepancy between available donor organs and those actually transplanted, by improving the preservation technology. The MAB provides guidance and recommendations for interacting with all the parties of the cardiac transplant community and providing insights into the donor organ procurement process and how the LifeCradle® should fit seamlessly into that process. OTS selected the MAB after evaluating their experience and passion for improving the donor organ procurement process and their willingness to share and be a part of the OTS team.
Dr. Kormos says that, "The OTS donor heart preservation technology incorporated in the LifeCradle® is based on very sound scientific research and is the best documented research for any donor heart preservation technology to date."